Alirocumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Alirocumab 是一种抑制 PCSK9 的人单克隆抗体。它是通过重组DNA技术在中国仓鼠卵巢细胞悬浮培养中生产的。

Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.

Cell Viability Assay Cell Line:hiPSC-CMs, hESC-CMs Concentration:0.01, 0.1, 1, 2, 10 μM Incubation Time: 24-72 h Result:Exhibited normal cell viability and did not affect the level of LDH release.

Animal Model:CETP mice model Dosage:3 or 10 mg/kg Administration:s.c.Result:Decreased total cholesterol dose-dependently.Increased hepatic LDL receptor protein levels but did not affect hepatic cholesterol and TG content.Decreased atherosclerotic lesion size and improved plaque morphology.Animal Model:Rat model (240-280 g) Dosage:10 mg/kg Administration:i.p.Result:Elevated ammonia, total cholesterol, LDL and ox-LDL levels.Decreased plasma levels of total cholesterol, LDL, and oxidative stress markers.

——

Others

PCSK9

PCSK9

——

——

1245916-14-6

146 kDa

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years